Home Blog of Signal Transduction Neuronal Signaling BACE

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

BACE

An isogenic panel of App knock-in mouse models: Profiling β-secretase inhibition and endosomal abnormalities

9 views | Jun 20 2022

Naoto Watamura et al. found that multiple factors, including elevated C-terminal fragment β (CTF-β) and humanization of Aβ might influence endosomal alterations in vivo. [Read the Full Post]

BACE1 controls synaptic function through modulating release of synaptic vesicles

0 views | Nov 16 2021

Brati Das et al. suggested that a therapy combining BACE1 inhibitors for reducing amyloid deposition and an mGluR1 PAM for counteracting BACE1-mediated synaptic deficits appeared to be an effective approach for treating AD patients. [Read the Full Post]

Spinal beta-amyloid1-42 acts as an endogenous analgesic peptide in CCI-induced neuropathic pain

148 views | Nov 15 2021

Dong Cui et al. suggested that spinal Aβ1-42 acted as an endogenous analgesic peptide through regulating cytokines and Wnt pathways. [Read the Full Post]

BACE1 controls synaptic function through modulating release of synaptic vesicles

232 views | Jul 29 2021

Brati Das et al. suggested that a therapy combining BACE1 inhibitors for reducing amyloid deposition and an mGluR1 PAM for counteracting BACE1-mediated synaptic deficits appeared to be an effective approach for treating AD patients. [Read the Full Post]

Selective Secretase Targeting for Alzheimer's Disease Therapy

247 views | May 05 2021

Alvaro Miranda et al. summarized structures and the activities of the latest compounds designed for AD treatment, with remarkable in vitro, in vivo, and clinical phase activities. [Read the Full Post]

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease

226 views | Nov 27 2020

Michael F Egan et al. thought that verubecestat was associated with increased risk for several types of adverse events. [Read the Full Post]

Quantification and Pharmacokinetic Property of Verubecestat an BACE1 Inhibitor in Rat Plasma

295 views | Jun 29 2020

Qiong Wang et al. designed an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) approach to measure the rat plasma levels of verubecestat with diazepam as the internal standard. [Read the Full Post]

BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines

0 views | Apr 05 2020

Blume T et al. suggested that carefully dosed inhibitors might be therapeutically effective without affecting the structural integrity of excitatory synapses if given at an early disease stage. [Read the Full Post]

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease

350 views | Feb 23 2020

Michael F Egan et al. indicated that verubecestat did not improve clinical ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo. [Read the Full Post]

Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

334 views | Feb 20 2020

Kyle C Cuneo et al. indicated that AZD1775 in combination with gemcitabine and radiation therapy was well tolerated at a dose that produced target engagement in a surrogate tissue. The overall survival is substantially higher than prior results combining gemcitabine with radiation therapy and warrants additional investigation. [Read the Full Post]